Core Viewpoint - The National Market Supervision Administration of China has imposed administrative penalties on four pharmaceutical companies for engaging in a monopoly agreement, resulting in a total fine exceeding 362 million yuan [1][2]. Group 1: Companies Involved - The companies involved in the monopoly agreement are Tianjin Pharmaceutical Industry Co., Ltd. (津药药业), Zhejiang Xianju Pharmaceutical Co., Ltd. (仙琚制药), Jiangsu Lianhuan Pharmaceutical Co., Ltd. (联环药业), and Xi'an Guokang Ruijin Pharmaceutical Co., Ltd. (国康瑞金制药) [1]. - Among these, Lianhuan Pharmaceutical, Tianjin Pharmaceutical, and Xianju Pharmaceutical hold the approval for the injection of dexamethasone phosphate sodium and have undergone consistency evaluation [2]. Group 2: Penalties and Financial Impact - The total fines imposed include 500,000 yuan on the individual responsible, confiscation of illegal gains, and an 8% fine on the previous year's sales for the four companies, amounting to approximately 355 million yuan [2]. - For Lianhuan Pharmaceutical, the penalty represents 2.83% of the company's audited revenue and 72.53% of the net profit attributable to shareholders for the most recent fiscal year [2]. - The penalty will reduce the net profit attributable to shareholders for Lianhuan Pharmaceutical by approximately 61.0382 million yuan for the fiscal year 2025 [2]. Group 3: Market Impact - The companies coordinated to raise the price of dexamethasone phosphate sodium from 8,000 yuan per kilogram to 13,000 yuan between February 2022 and March 2024, significantly restricting market competition and increasing healthcare costs for consumers [1].

证券代码：600488 证券简称：津药药业 编号：2025-050 津药药业股份有限公司 关于公司药品生产许可证变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 津药药业股份有限公司（以下简称"公司"）于近日完成了《药品生产许可 证》的变更登记并取到天津市药品监督管理局换发的《药品生产许可证》，本次 变更主要涉及新增委托生产。现将相关情况公告如下： 一、《药品生产许可证》基本情况 1.企业名称：津药药业股份有限公司 2.许可证编号：津20150001 3.社会信用代码：9112000071824811X4 4.分类码：BhDht 5.注册地址：天津开发区西区新业九街19号 6.法定代表人：李书箱 7.企业负责人：刘浩 8.质量负责人：白旸 9.质量受权人：白旸 11.有效日期至：2025年10月11日 12.生产地址和生产范围：天津开发区西区新业九街19号:麻醉药品（原料药 (盐酸布桂嗪))，原料药（氟米龙，醋酸泼尼松，丁酸氢化可的松，布地奈德， 卤米松，戊酸二氟可龙，二氟泼尼酯，地塞米松，依地酸钙钠，醋酸氢化 ...

108只ST股公布上半年业绩预告，净利润预盈公司共有11只。 证券时报·数据宝统计显示，截至8月6日，共有108只ST股公布了上半年业绩预告，业绩预告类型显示， 预盈公司共有11家，预亏公司有60家，减亏公司有30家。 以预告净利润上限进行统计，上半年净利润最高的是ST华通，预计实现净利润上限为30.00亿元，其次 是*ST松发、*ST仁东，上半年预计净利润上限分别为7.00亿元、4.00亿元。 业绩预计亏损的ST公司中，预计亏损金额最多的是ST晨鸣，上半年预计最小亏损额为35.00亿元，其次 是*ST金科、*ST中地，预计亏损金额分别为30.00亿元、11.90亿元。（数据宝） ST股业绩预告明细 | 002005 | ST德豪 | 减亏 | -1200.00 | -1800.00 | 54.49 | 家用电 | | --- | --- | --- | --- | --- | --- | --- | | | | | | | | 器 | | 600193 | *ST 创 | 预亏 | -1250.00 | -1550.00 | 26.25 | 建筑装 | | | 兴 | | | | | 饰 | | 00289 ...

Core Viewpoint - Tianjin Pharmaceutical Co., Ltd. is proposing to change its business scope, abolish the supervisory board, and amend its articles of association to enhance corporate governance and operational efficiency [1][3][4]. Business Scope Changes - The company plans to expand its business scope to include drug import and export, technology import and export, import and export agency, and goods import and export [1][8]. - The revised business scope will include the following licensed projects: drug production, entrusted drug production, veterinary drug production, cosmetics production, food additive production, feed additive production, hazardous chemicals operation, special equipment design, and drug import and export [1][8]. Articles of Association Amendments - The amendments to the articles of association aim to align with the Company Law and other relevant regulations, ensuring the protection of the rights of the company, shareholders, and creditors [3][4]. - Key changes include the removal of the supervisory board, with the audit and risk control committee of the board of directors assuming the supervisory functions [1][3]. - The articles will also clarify the responsibilities and rights of shareholders, including the ability to sue the company or its directors for breaches of duty [7][14]. Corporate Governance Enhancements - The company emphasizes the importance of maintaining a high standard of corporate governance to protect the interests of shareholders and ensure compliance with legal requirements [1][3]. - The amendments will also address the roles and responsibilities of the general manager and other senior management, ensuring accountability and legal compliance [5][6][7].

津药药业股份有限公司 2025 年第三次临时股东大会 津药药业股份有限公司 2025 年第三次临时股东大会 会议资料 2025 年 8 月 津药药业股份有限公司 2025 年第三次临时股东大会 津药药业 2025 年第三次临时股东大会会议议案之一 关于变更经营范围、取消监事会、修订《津药药业股 份有限公司章程》并办理工商变更的议案 1 / 99 津药药业股份有限公司 2025 年第三次临时股东大会 | 目录 | | --- | | 1.关于变更经营范围、取消监事会、修订《津药药业股份有限公司章 | | --- | | 程》并办理工商变更的议案 3 | | 2.关于修订《股东会议事规则》的议案 63 | | 3.关于修订《董事会议事规则》的议案 80 | | 4.关于修订《独立董事工作制度》的议案 91 | 2 / 99 (已经 2025 年 7 月 25 日第九届董事会第 19 次会议审议通过) 为提高公司规范运作水平，进一步完善公司治理制度，提升公司 运营效率，根据《公司法》《上市公司章程指引》等相关规定，公司 将不再设置监事会和监事，由董事会审计与风险控制委员会履行《公 司法》规定的监事会职权，同时，结合 ...

近日，津药药业股份有限公司（以下简称"公司"）收到天津市药品监督管理局签发的《药品GMP符合 性检查告知书》（编号：2025011），现将相关信息公告如下： 一、 基本情况 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 （二）涉及主要产品的市场情况 ■ 企业名称：津药药业股份有限公司 检查地址：天津开发区西区新业九街19号 检查范围：1.原料药(泼尼松)，生产车间:107车间，生产线:泼尼松生产B线；2.原料药(甲泼尼龙)，生产 车间:113车间，生产线:甲泼尼龙生产B线；3.原料药(氢化可的松琥珀酸钠)，生产车间:106车间，生产 线:氢化可的松琥珀酸钠生产线;4.原料药(富马酸福莫特罗)，生产车间:108车间，生产线:富马酸福莫特 罗生产线。 检查时间：2025年05月13日-2025年05月16日 检查依据：《药品生产质量管理规范》(2010年修订) 检查结论：符合要求 二、其他相关情况 （一）本次检查所涉及生产线及主要产品情况 ■ 注: 1.以上部分数据来源为国家药品监督管理局官方网站； 2.上述统计结果可能不 ...

Key Points - Tibet Tourism may apply for suspension of trading if significant abnormalities occur in stock transactions [1] - Southern Road Machinery's stock price has deviated from its fundamental situation [1] - Industrial Fulian's major customers and products have not undergone significant changes [1] - Yingweike has established a relatively complete liquid cooling technology and product solution capability [1] - Victory Energy's operational situation remains normal with no significant changes in the internal and external business environment [1] - Qizheng Tibetan Medicine's operational situation is normal with no significant changes in the internal and external business environment [1] - Dongxin Co. states that its investment in Shanghai Lishuan's chip products is not applicable for large model computing clusters [1] - Guosheng Co. has obtained project filing related to PEEK from its wholly-owned subsidiary [1] - Action Education's actual controller proposed a mid-term dividend of 10 yuan per 10 shares [1] Mergers and Acquisitions - Darui Electronics plans to acquire 80% of Weiste's equity through capital increase and share acquisition [1] - Dashengda intends to acquire 30% equity of Thailand's Far East [1] Financing - Aoshikang plans to issue convertible bonds not exceeding 1 billion yuan for high-end printed circuit board projects [1] - Sixuan New Materials intends to raise no more than 466 million yuan through a private placement [1] - Changhua Chemical plans to raise no more than 230 million yuan for a carbon dioxide polyether project [1] Share Buybacks and Reductions - Fuanna plans to repurchase shares worth between 55.85 million and 104 million yuan [1] - Jiangnan Yifan's board member intends to increase his stake in the company [1] - Jieya Co. and its concerted parties plan to reduce their holdings by no more than 4.95% [1] - Other companies including Tongda Co., Haohan Deep, and Wanhu Chemical also plan to reduce their holdings [1] Operational Data - Sinopec expects a net profit decline of 39.5% to 43.7% year-on-year for the first half of the year [1] - Qingdao Bank reported a net profit of 3.065 billion yuan for the first half, up 16.05% year-on-year [1] - Daodaquan's net profit increased by 563.15% year-on-year, proposing a dividend of 1.76 yuan per 10 shares [1] - Zhengdan Co. reported a net profit increase of 120.35% year-on-year, proposing a dividend of 3 yuan per 10 shares [1] - Other companies reported varying profit changes, including losses and significant increases [1] Contracts and Major Investments - Sanhui Electric signed a framework contract for robot equipment sales [1] - Zhejiang University Network New's subsidiary won a smart engineering project worth 94.2712 million yuan [1] - New Aluminum Times plans to invest no less than 500 million yuan in a project for lightweight, high-strength auto parts [1] - Zhishang Technology will use part of its raised funds for a smart manufacturing production base in Vietnam [1]

（文章来源：证券日报） 证券日报网讯 7月31日晚间，津药药业发布公告称，近日，公司收到天津市药品监督管理局签发的《药 品GMP符合性检查告知书》（编号：2025011）。 ...

证券代码：600488 证券简称：津药药业 编号：2025-049 津药药业股份有限公司 关于收到药品 GMP 符合性检查结果的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 近日，津药药业股份有限公司（以下简称"公司"）收到天津市药品监督管理局签 发的《药品 GMP 符合性检查告知书》（编号：2025011），现将相关信息公告如下： 一、 基本情况 企业名称：津药药业股份有限公司 检查地址：天津开发区西区新业九街 19 号 检查范围：1.原料药(泼尼松)，生产车间:107 车间，生产线:泼尼松生产 B 线；2. 原料药(甲泼尼龙)，生产车间:113 车间，生产线:甲泼尼龙生产 B 线；3.原料药(氢化可 的松琥珀酸钠)，生产车间:106 车间，生产线:氢化可的松琥珀酸钠生产线;4.原料药(富 马酸福莫特罗)，生产车间:108 车间，生产线:富马酸福莫特罗生产线。 检查时间：2025 年 05 月 13 日-2025 年 05 月 16 日 检查依据：《药品生产质量管理规范》(2010 年修订) 检查结论：符合要求 ...

Core Viewpoint - Tianjin Pharmaceutical Industry (津药药业) has received a GMP compliance inspection notice from the Tianjin Drug Administration, indicating that its production facilities for certain raw materials meet regulatory requirements, which is expected to support stable production capacity and leverage the integrated advantages of raw materials and formulations [2] Group 1 - The company received a GMP compliance inspection notice for its production facilities related to raw materials including prednisone, methylprednisolone, hydrocortisone sodium succinate, and formoterol fumarate [2] - The inspection concluded that the production facilities meet the required standards, which is beneficial for maintaining stable production capacity [2] - The integrated advantages of raw materials and formulations will help the company meet market demand [2] Group 2 - Future sales of the products may be influenced by changes in the market environment, indicating potential uncertainties [2]